Product Details
| Product Name:
Inavolisib |
CAS No.:
2060571-02-8 |
| Purity:
99.87% |
Supply Ability:
10g |
| Release date:
2025/11/10 |
Product Introduction
Bioactivity
| Name | Inavolisib |
| Description | Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
| In vitro | METHODS: Cell viability was assayed using Inavolisib (GDC-00777) up to 100 μmol/L in a panel of cancer cell lines.
RESULTS Inavolisib (GDC-00777) is a stronger cellular antiproliferative inducer. [1] |
| In vivo | METHODS: p110a protein depletion was studied in a p110a mutant xenograft breast cancer model using Inavolisib (GDC-0077) at a single oral dose of 50 mg/kgDC-0077.
RESULTS Inavolisib (GDC-0077) depleted p110a protein expression for up to 8 hours. [1] |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (24.55 mM), Solution.
DMSO : 240 mg/mL (589.15 mM), Sonication is recommended.
|
| Keywords | RG-6114 | RG 6114 | PI3Kα | PI3K | Phosphoinositide 3-kinase | Inhibitor | inhibit | Inavolisib | GDC0077 | GDC 0077 | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:55-10-7
$80.00 / 100mg
-
CAS:496-16-2
$29.00 / 1mL
-
CAS:138801-72-6
$82.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/10mg |
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-29 |
United States